FDA Guidance and Notices, September 2025: Final Computer Software Assurance Guidance and the LDT Rule Vacatur
September 2025 is when FDA wrote the court's vacatur of the laboratory developed test (LDT) rule into its regulations. Following the March 31 decision that vacated the 2024 rule, FDA published a final rule on September 19 returning the definition of in vitro diagnostic products to its earlier wording, and the same day withdrew two guidance documents for laboratory manufacturers, among them the LDT small entity compliance guide. Quality teams will also want the final guidance on computer software assurance for production and quality system software, issued September 24.
On September 30, the page for the CDRH Portal, the online submission portal of FDA's Center for Devices and Radiological Health (CDRH), began telling sponsors that from October 1 De Novo requests must be submitted with eSTAR (the electronic Submission Template And Resource), with limited exceptions. FDA also opened a request for comment that day on measuring and evaluating the real-world performance of AI-enabled medical devices. Earlier, on September 12, a Federal Register notice announced a Digital Health Advisory Committee meeting on generative AI-enabled digital mental health medical devices.
Final guidance
- Consideration of Enforcement Policies for In Vitro Diagnostic Tests During a Section 564 Declared Emergency (September 23): Sets out what FDA weighs when deciding enforcement policies for in vitro diagnostic tests during an emergency declared under section 564 of the FD&C Act.
- Computer Software Assurance for Production and Quality System Software (September 24): Covers computer software assurance for software used in production and in quality systems.
In the Federal Register
- General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments (September 3): Announces a General Hospital and Personal Use Devices Panel meeting on how to evaluate germicidal ultraviolet (UV) devices across their lifecycle, including performance testing, study design and user perspectives, and opens a docket for comments. The panel advises FDA and does not set requirements. The meeting date and comment deadline were later changed by a November 21 notice.
- Digital Health Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Generative Artificial Intelligence-Enabled Digital Mental Health Medical Devices (September 12): FDA sought input on benefits and risks, risk mitigation, premarket evidence and postmarket monitoring. The meeting was set for November 6, with comments due December 8.
- Radiological Health Regulations; Technical Amendments (September 18): Technical amendments to the radiological health regulations, effective on publication (September 18).
- Regulation Identification Number 0910-AJ05 Medical Devices; Laboratory Developed Tests; Implementation of Vacatur (September 19): Puts the definition of in vitro diagnostic products back to its pre-2024 wording after the court vacated the LDT rule on March 31, 2025. Effective September 19.
Device classification rules
Most of these write a classification decided earlier into the regulations; they do not mean any individual product was authorized that day. "Reclassification" changes a device type's class, and "proposed" marks a proposed rule open for comment.
- September 18: Reclassification: Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices
Safety communications and other updates
- Do Not Use Unauthorized Devices for Measuring Blood Pressure: FDA Safety Communication (September 16): Tells people not to use unauthorized products that claim to measure or estimate blood pressure, including software features on watches and rings, because wrong readings can delay diagnosis or treatment.
- Do Not Use Unauthorized Infant Devices for Monitoring Vital Signs: FDA Safety Communication (September 16): Warns about unauthorized monitors for infants' heart rate, oxygen saturation and other vital signs. FDA notes that they fall outside its general wellness policy and that no device is authorized to prevent sudden infant death syndrome (SIDS) or sudden unexpected infant death (SUID).
- Request For Public Comment: Measuring and Evaluating Artificial Intelligence-enabled Medical Device Performance in the Real-World (September 30): Asks for comments, due December 1, on how to measure and evaluate AI-enabled device performance in real-world use. It is a discussion paper, not a statement of regulatory expectations or policy.
- Send and Track Medical Device Premarket Submissions Online: CDRH Portal (September 30): The CDRH Portal page was updated to say that from October 1, 2025, De Novo requests must be submitted electronically with eSTAR, with limited exceptions.
Also this month
- September 19: FDA withdrew its May 2024 draft guidance on enforcement policy for certain IVDs used for immediate public health response without a section 564 declaration.
- September 19: The LDT small entity compliance guide (June 2024) was withdrawn the same day.
- September 25: FDA withdrew the January 2005 guidance on cybersecurity for networked medical devices containing off-the-shelf (OTS) software.
- September 25: The companion information for healthcare organizations, from February 2005, went with it.
- September 29: Early Alerts, which flag potentially high-risk removals and corrections before a recall is formally classified, were expanded from a pilot covering some devices to all medical devices.
Note: dates are FDA issue dates or Federal Register publication dates. Linked pages may now show a later version.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles